Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Molecules (Basel, Switzerland)
2025
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/39860176/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Isolation and Bioactivity of Natural Products from sp. MA37. Maglangit, Fleurdeliz Fang, Qing Tabudravu, Jioji N Kyeremeh, Kwaku Jaspars, Marcel Deng, Hai Streptomyces Biological Products Humans Siderophores Antineoplastic Agents MCF-7 Cells Cell Line, Tumor Molecular Structure Deferoxamine The isolation and characterization of bioactive metabolites from species continue to represent a vital area of research, given their potential in natural product drug discovery. In this study, we characterize a new siderophore called legonoxamine I, together with a known compound, streptimidone, from the talented soil bacterium sp. MA37, using chromatographic techniques and spectroscopic analysis. Legonoxamine I is a new holo-siderophore, which is likely to be a derailed product from the biosynthetic pathway of legonoxamine A. We also demonstrate that legonoxamine A possesses potent anticancer activity (IC = 2.2 µM), exhibiting a remarkable ~30-fold increase in potency against MCF-7 ATCC HTB-22 breast cancer cells compared to desferrioxamine B, a structural analogue of legonoxamine A (IC = 61.1 µM). Comparing the structural difference between legonoxamine A and desferrioxamine B, it is deduced that the phenylacetyl moiety in legonoxamine A may have contributed significantly to its enhanced potency. Our findings contribute to the growing library of -derived metabolites and underscore the genus' potential as a promising source of lead compounds.